Key result
Major progress has been made toward understanding the genetic basis, pathophysiology, and risk stratification of Brugada syndrome.
The paper reviews the progress made in understanding the genetic basis, pathophysiology, and risk stratification of Brugada syndrome in the context of epicardial substrate ablation.
Enhances risk stratification for Brugada syndrome; leaves open ablation efficacy pending randomized trials.
Brugada syndrome (BrS), characterized by the presence of coved-type ST-segment elevation followed by T-wave inversion in the right precordial electrocardiogram (ECG) leads in patients who have no structural heart disease but have a high risk of sudden cardiac death from ventricular fibrillation (VF), has captivated arrhythmia scholars and electrophysiologists for more than 2 decades. As a result, major progresses have been made toward a better understanding of the syndrome with respect to its genetic basis, underlying pathophysiology, and risk stratification.
No takes yet. Share an insight, caveat, or question.
Nademanee et al. (2016) conducted a review in Brugada syndrome. Epicardial substrate ablation was evaluated. Major progress has been made toward understanding the genetic basis, pathophysiology, and risk stratification of Brugada syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: